| (210) | Number of the EPO application | 16804054 |
| (220) | Filing date of the EPO application | 2016.05.26 |
| (80) | EPO patent specification publication (B) | EPB nr. 38/2021, 2021.09.22 |
| (110) | EPO patent number | 3302501 |
| (21) | Number of the application | e 2018 0365 |
| (71) | Name(s) of applicant(s), code of the country | MERCK SHARP & DOHME LLC, US;
Surefire Medical, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | YU Ying, US;
DENKER Andrew Evan, US;
SADEKOVA Svetlana, US;
PHAN Uyen Truong, US;
KASTELEIN Robert A., US;
KAUFMAN David Ross, US;
COFFMAN Robert L., US;
GUIDUCCI Cristiana, US;
JANSSEN Robert S., US; |
| (73) | Name(s) of owner(s), code of the country | MERCK SHARP & DOHME CORP., US;
TriSalus Life Sciences, Inc., US; |
| (54) | Title of the invention | COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/7115 (2006.01.01); A61K 39/39 (2006.01.01); A61K 45/06 (2006.01.01); A61K 9/00 (2006.01.01); A61N 5/00 (2006.01.01); C07K 14/435 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2018.05.31 |
| (30) | Priority | 201562168449 P, 2015.05.29, US; 201562169309 P, 2015.06.01, US |
| (86) | International application | PCT/US2016/034275, 2016.05.26 |
| (87) | International publication | WO 2016/196173, 2016.12.08 |